LGVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Longeveron Inc (LGVN) is not an ideal buy for a beginner, long-term investor at this time. While the company has positive developments in its patent portfolio and clinical trial progress, its financial performance is weak, with declining revenue and negative net income. The technical indicators show a neutral to slightly bullish trend, but the lack of strong trading signals and the recent analyst price target reduction suggest limited upside in the near term.
The MACD is positive and contracting, indicating a slight bullish momentum. The RSI is neutral at 60.883, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of 1.189, with a pivot at 1.054. However, the stock has a 50% chance of declining in the short term based on historical patterns.
Longeveron has been granted a new patent in China, extending its patent rights until
The company has received five key FDA designations to expedite clinical trials.
The Phase 2b clinical trial for HLHS is ongoing, with results expected in Q3 2026.
Revenue dropped significantly by -39.47% YoY in Q4
Analyst price target was lowered from $3 to $2, reflecting reduced confidence in near-term performance.
Historical stock trends suggest a potential decline in the short term.
In Q4 2025, revenue dropped to $365,000 (-39.47% YoY), while net income improved to -$5,444,000 (+33.40% YoY). EPS increased to -0.39 (+44.44% YoY), and gross margin improved slightly to 91.24% (+3.81% YoY). Despite some improvements in net income and EPS, the overall financial performance remains weak.
Roth Capital maintains a Buy rating but lowered the price target from $3 to $2. The firm expects top-line data from the ELPIS II study in Q3 2026, with a potential BLA filing in 2027 if results are positive.
